scholarly journals Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis

2017 ◽  
Author(s):  
Iwona Hus ◽  
Adam Walter-Croneck ◽  
Anna Masternak ◽  
Artur Jurczyszyn ◽  
Lidia Usnarska–Zubkiewicz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Life Experience ◽  
Real Life ◽  
Newly Diagnosed ◽  
Multicenter Analysis

scholarly journals How I manage frontline transplant-ineligible multiple myeloma

2020 ◽  
Vol 12 (s1) ◽  
Author(s):  
Daniele Derudas ◽  
Francesca Capraro ◽  
Giovanni Martinelli ◽  
Claudio Cerchione
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cells ◽  
Life Experience ◽  
Hematological Malignancy ◽  
Real Life ◽  
Standard Of Care ◽  
Newly Diagnosed ◽  
Safety And Efficacy ◽  
Frailty Status ◽  
Careful Assessment

The Multiple Myeloma (MM) is a plasma cells hematological malignancy with a median age of 69 years at diagnosis. The autologous stem cell transplantation is the standard of care for this disease but less than half of newly diagnosed patients are assessed for this treatment due to comorbidities or complications of disease. The management of transplant ineligible MM patients is based on the balance safety and efficacy of the new available regimen and a careful assessment of the frailty status is mandatory to define the goals. In this review we discuss of the clinical dilemmas in the management and define how to manage them based on the evidence from clinical trials and “real life” experience.

scholarly journals Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study

2020 ◽  
Vol 99 (11) ◽  
pp. 2589-2598
Author(s):  
Jing Li ◽  
Li Bao ◽  
Zhongjun Xia ◽  
Sili Wang ◽  
Xin Zhou ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Induction Therapy ◽  
Response Rate ◽  
Real Life ◽  
Comparable Efficacy ◽  
Routine Practice ◽  
Newly Diagnosed ◽  
Efficacy And Safety ◽  
Frontline Therapy ◽  
Grade 3

Abstract The induction therapy containing ixazomib, an oral proteasome inhibitor, has shown favorable efficacy and safety in clinical trials, but its experience in real-life remains limited. In routine practice, few patients received ixazomib-based induction therapy due to reasons including (1) patients’ preference on oral regimens, (2) concerns on adverse events (AEs) of other intravenous/subcutaneous regimens, (3) requirements for less center visits, and (4) fears of COVID-19 and other infectious disease exposures. With the aim of assessing the real-life effectiveness and safety of ixazomib-based induction therapy, we performed this multi-center, observational study on 85 newly diagnosed multiple myeloma (NDMM) patients from 14 medical centers. Ixazomib-based regimens included ixazomib-lenalidomide-dexamethasone (IRd) in 44.7% of patients, ixazomib-dexamethasone (Id) in 29.4%, and Id plus another agent (doxorubicin, cyclophosphamide, thalidomide, or daratumumab) in 25.9%. Different ixazomib-based therapies were applied due to (1) financial burdens or limitations on local health insurance coverage, (2) concerns on treatment tolerance, and (3) drug accessibility issue. Ten patients received ixazomib maintenance. The median age was 67 years; 43.5% had ISS stage III disease; 48.2% had an Eastern Cooperative Oncology Group performance score ≥ 2; and 17.6% with high-risk cytogenetic abnormalities. Overall response rate for all 85 patients was 95.3%, including 65.9% very good partial response or better and 29.5% complete responses. The median time to response was 30 days. The response rate was similar across different ixazomib-based regimens. Median progression-free survival was not reached. Severe AEs (≥ grade 3) were reported in 29.4% of patients. No grade 3/4 peripheral neuropathy (PN) occurred. Patients received a median of 6 (range 1–20) cycles of ixazomib treatment; 56.6% remained on treatment at data cutoff; 15.3% discontinued treatment due to intolerable AEs. These results support that the ixazomib-based frontline therapy was highly effective with acceptable toxicity in routine practice and the ixazomib oral regimens could be good alternative options for NDMM patients.

Lenalidomide at the Dose of Twenty-five mg Every Other Day in Patients Affected by Multiple Myeloma and Renal Failure: A Real-life Experience

2017 ◽  
Vol 17 (1) ◽  
pp. e122
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuele Pareto ◽  
Davide Nappi ◽  
Ilaria Peluso ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Life Experience ◽  
Real Life

Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience

2017 ◽  
Vol 17 ◽  
pp. S343
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuele Pareto ◽  
Santina Basile ◽  
Luana Marano ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Life Experience ◽  
Real Life ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document